Advertisement
Canada markets open in 5 hours 13 minutes

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7293
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    79.71
    +0.71 (+0.90%)
     

  • Bitcoin CAD

    79,203.31
    +656.77 (+0.84%)
     

  • CMC Crypto 200

    1,263.24
    -7.50 (-0.59%)
     

  • GOLD FUTURES

    2,319.50
    +8.50 (+0.37%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,580.25
    +142.00 (+0.81%)
     

  • VOLATILITY

    15.02
    -0.37 (-2.40%)
     

  • FTSE

    8,157.08
    +35.84 (+0.44%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6806
    +0.0013 (+0.19%)
     

Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference

Business Wire
·1 min read

GERMANTOWN, Md., March 06, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.

Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306655647/en/

Contacts

Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com